Ghent University Academic Bibliography

Advanced

The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES)

O Bruyere, JA Kanis, ME Ibar-Abadie, N Alsayed, ML Brandi, N Burlet, DL Cahall, A Chines, JP Devogelaer, W Dere, et al. (2010) OSTEOPOROSIS INTERNATIONAL. 21(5). p.713-722
abstract
This paper provides recommendations for fair and unbiased relationship between academic scientists and the pharmaceutical industry. Real or perceived problems in the relationship between academics and the industry have been the subject of much recent debate. It has been suggested that academic clinicians should sever all links with the industry-a view that is rarely challenged. Academic experts and members of the pharmaceutical industry were invited to an expert consensus meeting to debate this topic. This meeting was organized by the Group for the Respect of Ethics and Excellence in Science. Conflict of interest, competing interest, right and duties of academic scientist, authorship, and staff and student education were discussed. Guidelines for a transparent, ethical, strong, and successful partnership between the academic scientist and the pharmaceutical industry have been provided. The Group support interactions between the industry and clinicians provided that it is transparent and ethical.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
GOOD PUBLICATION PRACTICE, CONFLICT-OF-INTEREST, FINANCIAL CONFLICTS, BIOMEDICAL-RESEARCH, MEDICAL-EDUCATION, CLINICAL-PRACTICE, TRIAL OUTCOMES, RECOMMENDATIONS, REGISTRATION, DRUGS, Competing interest, Conflict of interest, Ethics, Ghost authorship, Medical education
journal title
OSTEOPOROSIS INTERNATIONAL
Osteoporosis Int.
volume
21
issue
5
pages
713 - 722
Web of Science type
Article
Web of Science id
000276075600002
JCR category
ENDOCRINOLOGY & METABOLISM
JCR impact factor
4.859 (2010)
JCR rank
23/115 (2010)
JCR quartile
1 (2010)
ISSN
0937-941X
DOI
10.1007/s00198-010-1190-9
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
1194268
handle
http://hdl.handle.net/1854/LU-1194268
date created
2011-03-22 14:27:03
date last changed
2016-12-19 15:45:14
@article{1194268,
  abstract     = {This paper provides recommendations for fair and unbiased relationship between academic scientists and the pharmaceutical industry. Real or perceived problems in the relationship between academics and the industry have been the subject of much recent debate. It has been suggested that academic clinicians should sever all links with the industry-a view that is rarely challenged. Academic experts and members of the pharmaceutical industry were invited to an expert consensus meeting to debate this topic. This meeting was organized by the Group for the Respect of Ethics and Excellence in Science. Conflict of interest, competing interest, right and duties of academic scientist, authorship, and staff and student education were discussed. Guidelines for a transparent, ethical, strong, and successful partnership between the academic scientist and the pharmaceutical industry have been provided. The Group support interactions between the industry and clinicians provided that it is transparent and ethical.},
  author       = {Bruyere, O and Kanis, JA and Ibar-Abadie, ME and Alsayed, N and Brandi, ML and Burlet, N and Cahall, DL and Chines, A and Devogelaer, JP and Dere, W and Goel, N and Hughes, N and Kaufman, Jean and Korte, S and Mitlak, BH and Niese, D and Rizzoli, R and Rovati, LC and Reginster, JY},
  issn         = {0937-941X},
  journal      = {OSTEOPOROSIS INTERNATIONAL},
  keyword      = {GOOD PUBLICATION PRACTICE,CONFLICT-OF-INTEREST,FINANCIAL CONFLICTS,BIOMEDICAL-RESEARCH,MEDICAL-EDUCATION,CLINICAL-PRACTICE,TRIAL OUTCOMES,RECOMMENDATIONS,REGISTRATION,DRUGS,Competing interest,Conflict of interest,Ethics,Ghost authorship,Medical education},
  language     = {eng},
  number       = {5},
  pages        = {713--722},
  title        = {The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES)},
  url          = {http://dx.doi.org/10.1007/s00198-010-1190-9},
  volume       = {21},
  year         = {2010},
}

Chicago
Bruyere, O, JA Kanis, ME Ibar-Abadie, N Alsayed, ML Brandi, N Burlet, DL Cahall, et al. 2010. “The Need for a Transparent, Ethical, and Successful Relationship Between Academic Scientists and the Pharmaceutical Industry: a View of the Group for the Respect of Ethics and Excellence in Science (GREES).” Osteoporosis International 21 (5): 713–722.
APA
Bruyere, O., Kanis, J., Ibar-Abadie, M., Alsayed, N., Brandi, M., Burlet, N., Cahall, D., et al. (2010). The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). OSTEOPOROSIS INTERNATIONAL, 21(5), 713–722.
Vancouver
1.
Bruyere O, Kanis J, Ibar-Abadie M, Alsayed N, Brandi M, Burlet N, et al. The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). OSTEOPOROSIS INTERNATIONAL. 2010;21(5):713–22.
MLA
Bruyere, O, JA Kanis, ME Ibar-Abadie, et al. “The Need for a Transparent, Ethical, and Successful Relationship Between Academic Scientists and the Pharmaceutical Industry: a View of the Group for the Respect of Ethics and Excellence in Science (GREES).” OSTEOPOROSIS INTERNATIONAL 21.5 (2010): 713–722. Print.